Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases

Clinical trial NCT07644754 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07644754
Sponsor: University Hospital Tuebingen
Status: NOT_YET_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Prostate Cancer Prostate Cancer Metastatic Disease Prostate Cancer Metastatic to Bone

Start date: 2026-07-01
Primary completion: 2027-07-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.